See more : Nichirei Corporation (2871.T) Income Statement Analysis – Financial Results
Complete financial analysis of electroCore, Inc. (ECOR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of electroCore, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Yunnan Metropolitan RealEstate Development Co.Ltd (600239.SS) Income Statement Analysis – Financial Results
- Times Guaranty Limited (TIMESGTY.NS) Income Statement Analysis – Financial Results
- Crown Castle Inc. (CCI) Income Statement Analysis – Financial Results
- Subaru Co., Ltd. (9778.T) Income Statement Analysis – Financial Results
- BJ’s Wholesale Club Holdings, Inc. (BJ) Income Statement Analysis – Financial Results
electroCore, Inc. (ECOR)
About electroCore, Inc.
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 16.03M | 8.59M | 5.45M | 3.50M | 2.39M | 992.95K | 811.46K | 254.14K |
| Cost of Revenue | 2.80M | 1.62M | 1.39M | 1.74M | 1.16M | 578.74K | 518.53K | 123.73K |
| Gross Profit | 13.23M | 6.98M | 4.07M | 1.76M | 1.23M | 414.21K | 292.93K | 130.41K |
| Gross Profit Ratio | 82.51% | 81.19% | 74.59% | 50.30% | 51.59% | 41.71% | 36.10% | 51.31% |
| Research & Development | 5.32M | 5.52M | 2.54M | 4.20M | 9.90M | 12.47M | 7.83M | 7.97M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 42.50M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 26.71M | 24.33M | 21.57M | 21.84M | 35.42M | 42.50M | 18.11M | 7.17M |
| Other Expenses | 0.00 | -6.00K | -8.30K | -17.80K | -12.00K | -344.91K | -4.89K | 7.17M |
| Operating Expenses | 32.03M | 29.85M | 24.11M | 26.04M | 45.32M | 54.97M | 25.94M | 15.14M |
| Cost & Expenses | 34.84M | 31.47M | 25.49M | 27.78M | 46.48M | 55.55M | 26.46M | 15.26M |
| Interest Income | 433.00K | 287.00K | 10.70K | 84.30K | 970.59K | 1.01M | 99.03K | 0.00 |
| Interest Expense | 0.00 | 287.00K | 0.00 | 8.34K | 0.00 | 0.00 | 7.12M | 771.25K |
| Depreciation & Amortization | 1.03M | 596.00K | 436.62K | 489.47K | 307.36K | 66.66K | 32.31K | 53.43K |
| EBITDA | -17.76M | -22.33M | -19.66M | -24.18M | -43.98M | -54.49M | -28.87M | -14.96M |
| EBITDA Ratio | -110.79% | -266.22% | -403.85% | -681.37% | -1,761.26% | -5,420.74% | -3,144.73% | -5,885.31% |
| Operating Income | -18.81M | -22.87M | -20.04M | -24.28M | -44.09M | -54.55M | -25.64M | -15.01M |
| Operating Income Ratio | -117.31% | -266.22% | -367.68% | -694.66% | -1,844.81% | -5,494.07% | -3,160.31% | -5,906.33% |
| Total Other Income/Expenses | -215.00K | 281.00K | 1.97M | -398.04K | -1.04M | -1.21M | -10.38M | -771.25K |
| Income Before Tax | -19.02M | -22.59M | -18.07M | -24.68M | -45.13M | -55.76M | -36.03M | -15.78M |
| Income Before Tax Ratio | -118.65% | -262.95% | -331.47% | -706.05% | -1,888.24% | -5,615.88% | -4,440.01% | -6,209.81% |
| Income Tax Expense | -186.00K | -431.00K | -851.20K | -1.17M | 18.00K | 2.43K | 6.88M | -44.15K |
| Net Income | -18.83M | -22.16M | -17.22M | -23.51M | -45.15M | -55.82M | -35.79M | -15.74M |
| Net Income Ratio | -117.49% | -257.94% | -315.86% | -672.55% | -1,889.00% | -5,621.66% | -4,410.88% | -6,192.44% |
| EPS | -3.42 | -4.69 | -4.36 | -9.04 | -23.05 | -28.61 | -1.36 | -1.57 |
| EPS Diluted | -3.42 | -4.69 | -4.36 | -9.04 | -23.05 | -28.61 | -1.36 | -1.57 |
| Weighted Avg Shares Out | 5.52M | 4.73M | 3.95M | 2.60M | 1.96M | 1.95M | 26.34M | 10.04M |
| Weighted Avg Shares Out (Dil) | 5.52M | 4.73M | 3.95M | 2.60M | 1.96M | 1.95M | 26.34M | 10.04M |
electroCore Expands Intellectual Property Portfolio for Nerve Stimulation Technology
ROCKAWAY, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to a system for stimulating a nerve...
Dr. Peter Staats to Host Analyst Day on the Science Behind gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) on Tuesday, November 21, 2023
ROCKAWAY, N.J., Nov. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company's Chief Medical Officer, Dr. Peter Staats will host an analyst day entitled “Accessing the Power of...
electroCore, Inc. (ECOR) Q3 2023 Earnings Call Transcript
electroCore, Inc. (NASDAQ:ECOR ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Dan Goldberger – Chief Executive Officer Brian Posner – Chief Financial Officer Conference Call Participants Destiny Hance – Ladenburg Thalmann Ramakanth Swayampakula –...
electroCore Announces Third Quarter 2023 Financial Results
Record third quarter 2023 net sales of $4.5 million, an increase of approximately 128% over third quarter 2022 Company increases revenue guidance for full year 2023 to $15.0 million - $15.5 million Company to host a conference call and webcast today, November...
electroCore to Participate in Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum
ROCKAWAY, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, is scheduled to attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services...
Data Highlighting Non-invasive Vagus Nerve Stimulation (nVNS) for Treatment of Symptoms of Gastroparesis Presented at 2023 American College of Gastroenterology Annual Meeting
Clinical Trial suggests nVNS can reduce the use of rescue medications for exacerbations of nausea due to Gastroparesis or Functional Dyspepsia Clinical Trial suggests nVNS can reduce the use of rescue medications for exacerbations of nausea due to Gastroparesis or...
electroCore Announces Two-Year Extension of gammaCore™ Device Listing in the NHS Supply Chain Catalogue
ROCKAWAY, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial stage bioelectronic medicine and wellness company, announced today that gammaCore therapy will continue to be listed in the United Kingdom's National Health Service (NHS) Supply Chain...
electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology
ROCKAWAY, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to a treatment protocol for nVNS.
Data Highlighting Non-Invasive Vagus Nerve Stimulation (nVNS) for Treatment of Acute Neurological Injury Presented at 2023 World Stroke Congress
“VANQUISH” Clinical Trial (n=40) suggests safety and efficacy of nVNS for the Treatment of Headache Associated with Subarachnoid Hemorrhage (SAH)
electroCore to Announce Third Quarter Financial Results on Wednesday, November 8
ROCKAWAY, N.J., Oct. 09, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the third quarter ended September 30, 2023, after the close of the market on Wednesday,...
Source: https://incomestatements.info
Category: Stock Reports